News Anchor, Pregnant When Diagnosed with NHL, Reaches Remission

Michelle Kingsfield, nightly news anchorwoman for WRGT and WKEF television news in Dayton, Ohio was given the good news this week that she is in remission from stage 4 Non-Hodgkin's Lymphoma.



She returned from a CAT scan and complete checkup on Thursday and has been informed by her medical specialists that she remains in remission, and her chances of a recurrence of the Non-Hodgkins lymphoma are minimal. "It is amazing. I am feeling better every day," she said.



What was even more amazing about Kingsfield's experience was that she was four months pregnant at the time of her diagnosis. Her medical team prescribed a type of chemotherapy that does not harm the baby. Her son, Robert Kingsfield Edgerley, who she was carrying when the cancer was detected, did not suffer effects from the chemotherapy. He will be celebrating his first birthday April 27. Michelle was featured on the national morning show Good Morning America almost a year ago with details of her story.



Kingsfield and her husband, Steve Edgerley, a teacher, and their son Casey, 3, will not only be observing Robert's birthday, but it will be "a celebration of life and survival," Kingsfield said. More in the Dayton Daily News

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap